Erin Clancy

5 days ago | cancertherapyadvisor.com | Erin Clancy

Adjuvant cemiplimab can improve disease-free survival (DFS) in patients with cutaneous squamous cell carcinoma (CSCC) who have completed adjuvant radiotherapy and have a high risk of recurrence, according to research presented at the ASCO Annual Meeting 2025.1 “[C]emiplimab is the only systemic therapy to demonstrate a statistically significant and clinically meaningful reduction in disease recurrence as adjuvant therapy for patients at high risk of CSCC recurrence,” said study presenter...

5 days ago | shorturl.at | Erin Clancy

Adjuvant cemiplimab can improve disease-free survival (DFS) in patients with cutaneous squamous cell carcinoma (CSCC) who have completed adjuvant radiotherapy and have a high risk of recurrence, according to research presented at the ASCO Annual Meeting 2025.1 “[C]emiplimab is the only systemic therapy to demonstrate a statistically significant and clinically meaningful reduction in disease recurrence as adjuvant therapy for patients at high risk of CSCC recurrence,” said study presenter...

1 week ago | hematologyadvisor.com | Erin Clancy

A symptom assessment intervention can reduce acute care use and costs for older adults with cancer, according to a study presented at the ASCO Annual Meeting 2025. The study included 416 patients who had newly diagnosed or relapsed cancer, were 75 years of age and older, and were insured by a Medicare Advantage payer partner. The patients’ median age was 82 years, and 41.4% had stage IV disease.

1 week ago | shorturl.at | Erin Clancy

A symptom assessment intervention can reduce acute care use and costs for older adults with cancer, according to a study presented at the ASCO Annual Meeting 2025. The study included 416 patients who had newly diagnosed or relapsed cancer, were 75 years of age and older, and were insured by a Medicare Advantage payer partner. The patients’ median age was 82 years, and 41.4% had stage IV disease.

1 week ago | clinicaladvisor.com | Erin Clancy

The US Food and Drug Administration (FDA) is adopting a new regulatory framework that will change the criteria for approval of COVID-19 vaccines and ultimately limit who can be vaccinated, according to a viewpoint by FDA officials that was published in The New England Journal of Medicine.1 The FDA will continue to evaluate individual applications for COVID-19 vaccines on a case-by-case basis, but the agency will adopt different standards for approval according to the patient populations...